Anti-inflammatory agents: determination of ibuproxam and its metabolite humans. Correlation between bioavailability, tolerance and chemico-physical characteristics.
A study on absorption and elimination in the urine of 2-(4-isobutylphenyl)-propiohydroxamic acid (ibuproxam, Ibudros) (400 mg film tablets) after administration to healthy volunteers is reported. In the plasma, only a minimum concentration of ibuproxam as such could be found: instead its chief metabolite ibuprofen mainly present, with top peaks at 45 min. The maximum ibuprofen concentration in the plasma--when obtained through metabolization of ibuproxam--is significantly higher than after administration of an equal dose of ibuprofen. This phenomenon is related to the chemico-physical characteristics of the two compounds.
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000378:metabolism*; D044482:Benzeneacetamides; D001682:Biological Availability; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000378:metabolism*; D007408:Intestinal Absorption; D007700:Kinetics; D008297:Male; D012995:Solubility
D000893:Anti-Inflammatory Agents; D044482:Benzeneacetamides; D006877:Hydroxamic Acids; C025377:ibuproxam